Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | |||||||||||||
Title | Kymriah (tisagenlecleucel) FDA Drug Label | ||||||||||||
|
|||||||||||||
URL | https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Tisagenlecleucel | Tisagenlecleucel | 0 | 15 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tisagenlecleucel | Kymriah | CTL019 | Kymriah (tisagenlecleucel) is a preparation of autologous T-lymphocytes engineered to express chimeric antigen receptors targeting CD19-positive cells, resulting in anti-tumor immune response (J Clin Oncol 35, 2017 (suppl; abstr 10523)). Kymriah (tisagenlecleucel) is FDA approved for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia, adult patient with relapsed or refractory large B-cell lymphoma, and adult patients with relapsed or refractory follicular lymphoma (FDA.gov). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|